Down-regulation of Akt signaling with HIV-1 protease inhibitors

Down-regulation of Akt signaling with HIV-1 protease inhibitors

Detalles Bibliográficos
Main Authors:	Gupta, A, Cerniglia, G, Mick, R, Mckenna, W, Muschel, R
Formato:	Conference item
Publicado:	2005

Títulos similares

HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo.
por: Gupta, A, et al.
Publicado: (2005)

Phosphorylation of glycogen sythase kinase-3 beta does not contribute to radiation resistance in two cell lines with activation of the Akt pathway
por: Gupta, A, et al.
Publicado: (2004)

Computational investigations of HIV-1 protease and protease inhibitors interactions
por: Sham, Hoi Fung
Publicado: (2014)

The use of signal transduction inhibitors with radiation
por: Mckenna, W, et al.
Publicado: (2006)

Additivity in the Analysis and Design of HIV Protease Inhibitors
por: Jorissen, Robert N., et al.
Publicado: (2012)

Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002.
por: Gupta, A, et al.
Publicado: (2003)

A phase I-trial of the HIV protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer
por: Brunner, T, et al.
Publicado: (2008)

A phase I-trial of the HIV protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer
por: Brunner, T, et al.
Publicado: (2008)

An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses.
por: André, P, et al.
Publicado: (1998)

Molecular docking of HIV-1 protease inhibitors using open source software /
por: 368807 Alvin Alexander Idin, et al.
Publicado: (2007)

Substrate Envelope-Designed Potent HIV-1 Protease Inhibitors to Avoid Drug Resistance
por: Nalam, Madhavi N. L., et al.
Publicado: (2016)

Progress towards the use of HIV protease inhibitors in cancer therapy
por: Bernhard, E, et al.
Publicado: (2008)

Progress towards the use of HIV protease inhibitors in cancer therapy.
por: Bernhard, E, et al.
Publicado: (2008)

Farnesyltransferase inhibitors as radiation sensitizers.
por: Mckenna, W, et al.
Publicado: (2002)

Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction.
por: Gupta, A, et al.
Publicado: (2002)

MicroRNA-31 inhibits lung adenocarcinoma stem-like cells via down-regulation of MET-PI3K-Akt signaling pathway
por: Hou, C, et al.
Publicado: (2016)

C-Raf-1 protein kinase is not essential for Ras transformation of mouse embryo fibroblasts.
por: Gupta, A, et al.
Publicado: (2003)

HIV-1 down-regulates the expression of CD1d via Nef.
por: Chen, N, et al.
Publicado: (2006)

A rodent model of HIV protease inhibitor indinavir induced peripheral neuropathy
por: Huang, W, et al.
Publicado: (2016)

Activation of Akt and the signaling of phosphorylated Akt in the L5 dorsal root ganglia in aging rats
por: Yon, H.M., et al.
Publicado: (2017)

Protease nexin 1: a novel regulator of prostate cancer cell growth and neo-angiogenesis.
por: McKee, C, et al.
Publicado: (2013)

Farnesyltransferase inhibitors as radiation sensitizers.
por: Brunner, T, et al.
Publicado: (2003)

Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS.
por: Cohen-Jonathan, E, et al.
Publicado: (2000)

Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations.
por: Brunner, T, et al.
Publicado: (2003)

Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma.
por: McKee, C, et al.
Publicado: (2012)

The HIV protease inhibitor indinavir reduces immature dendritic cell transendothelial migration.
por: Whelan, K, et al.
Publicado: (2003)

Signaling pathways in NSCLC as a predictor of outcome and response to therapy.
por: Gupta, A, et al.
Publicado: (2004)

Live cell imaging reveals distinct roles in cell cycle regulation for Nek2A and Nek2B.
por: Fletcher, L, et al.
Publicado: (2005)

Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines.
por: Kim, I, et al.
Publicado: (2005)

Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa
por: Boender, T, et al.
Publicado: (2016)

Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
por: Generali, D, et al.
Publicado: (2008)

Evolution of protease inhibitor resistance in HIV-1-infected patients failing protease inhibitor monotherapy as second-line therapy in low-income countries: an observational analysis within the EARNEST randomised trial
por: Thompson, J, et al.
Publicado: (2018)

Matrix metalloproteinase-9 regulates tumor cell invasion through cleavage of protease nexin-1.
por: Xu, D, et al.
Publicado: (2010)

Impaired Striatal Akt Signaling Disrupts Dopamine Homeostasis and Increases Feeding
por: Speed, Nicole, et al.
Publicado: (2013)

HIV-1 protease as a target for antiretroviral therapy
por: Windsor, Ian William.
Publicado: (2019)

Gag and protease co-evolution modeling for HIV-1
por: Wang, Junjie
Publicado: (2014)

Appearance of a single amino acid insertion at position 33 in HIV type 1 protease under a lopinavir-containing regimen, associated with reduced protease inhibitor susceptibility.
por: Magiorkinis, E, et al.
Publicado: (2011)

AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer
por: Sandy, Peter, et al.
Publicado: (2015)

Akt regulation of glycolysis mediates bioenergetic stability in epithelial cells
por: Hung, Yin P, et al.
Publicado: (2018)

MEDI 281-Substrate-mimetic inhibitors of Akt as potential anti-cancer therapeutics
por: Kayser, K, et al.
Publicado: (2006)